Literature DB >> 2358804

The interactions of monoamine oxidase with some derivatives of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

J P Sullivan1, K F Tipton.   

Abstract

The interactions of a number of derivatives of the dopaminergic neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) with monoamine oxidase (MAO) have been studied. The desmethyl derivative, 4-phenyl-1,2,3,6-tetrahydropyridine (PTP), was oxidised by MAO-B to form the corresponding dihydropyridine. Initial interaction with both forms of MAO was competitive. However the degree of inhibition of MAO-B, but not MAO-A, increased with time and became irreversible. Substitution of a methyl group at the 6-position of the heterocyclic ring of MPTP prevented it from acting as a substrate for MAO-B and greatly decreased its potency as an inhibitor of that form of MAO, although it remained a good competitive inhibitor of MAO-A. Replacement of the tetrahydropyridine ring of PTP by piperidine apparently abolished the ability to act as a substrate for MAO-B. The compound was however a competitive inhibitor of both forms of MAO. Substitution of a 3-(chlorophenyl)-methoxy-group at the 4'-position of this compound and PTP led to compounds which appeared to be devoid of substrate activity although they were potent, highly-selective, time-dependent inhibitors of MAO-B.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2358804     DOI: 10.1007/978-3-7091-9050-0_26

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  2 in total

1.  Interactions of the neurotoxin MPTP and its demethylated derivative (PTP) with monoamine oxidase-B.

Authors:  J P Sullivan; K F Tipton
Journal:  Neurochem Res       Date:  1992-08       Impact factor: 3.996

2.  Successful Treatment of Intracranial Glioblastoma Xenografts With a Monoamine Oxidase B-Activated Pro-Drug.

Authors:  Martyn A Sharpe; Andrew D Livingston; Taylor L Gist; Pardip Ghosh; Junyan Han; David S Baskin
Journal:  EBioMedicine       Date:  2015-08-08       Impact factor: 8.143

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.